Summaries of health policy coverage from major news organizations
Japanese Firm to Test 10-Year-Old Drug’s HIV Treatment Potential in United States
Zeria Pharmaceutical Co. Ltd., a Japanese company, announced Wednesday that it will hold clinical trials for the potential HIV/AIDS drug Ancer 20 Injection in the United States, Reuters reports. At a global conference on AIDS in South Africa last summer, Zeria announced that Ancer 20 Injection, originally developed and used to sustain white blood cell counts in cancer patients, may be effective against HIV because it "seems to help block the virus from entering cells." Japanese doctors have used the drug for the last decade in cancer patients undergoing radiation treatments, and although it is not currently used to treat HIV, a Zeria spokesperson said that the company will apply for permission to treat HIV patients if it receives FDA approval (Reuters, 1/16).
This is part of the KHN Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.